Presentation is loading. Please wait.

Presentation is loading. Please wait.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

Published byAmi Hutchinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary."— Presentation transcript:

1 Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness.
Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Harnessing the power of systems biology may provide explanations for discrepancies between in vitro/in vivo experiments and clinical trial results. These indicators can then be incorporated into more finely tuned experiments, which should result in more effective treatments. Maria Molina-Molina et al. ERJ Open Res 2017;3: ©2017 by European Respiratory Society

Download ppt "Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary."

Similar presentations

Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.

Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.
Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.
Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.

Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.
Echocardiography view

Echocardiography view
Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.

Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.
Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.

Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.
Demographics of IPF in the USa-d

Demographics of IPF in the USa-d
Translation from endotype to phenotype, variants and comorbidities.

Translation from endotype to phenotype, variants and comorbidities.
Serial imaging while on immunosuppressive therapy (two subjects).

Serial imaging while on immunosuppressive therapy (two subjects).
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.

Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Survival without tracheostomy

Survival without tracheostomy
Readthrough levels measured for the indicated cystic fibrosis transmembrane conductance regulator (CFTR) premature termination codon mutations, at basal.

Readthrough levels measured for the indicated cystic fibrosis transmembrane conductance regulator (CFTR) premature termination codon mutations, at basal.
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.

The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Similar presentations

Ads by Google